FindTrial
Sign In

To study Biomarker CD30 in Diffuse Large B-cell Lymphoma

The Expression of CD30 in Diffuse Large B-cell Lymphoma by Immunohistochemistry

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2021/07/034856
Enrollment
25
Registered
2021-07-14
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C858- Other specified types of non-Hodgkin lymphoma

Interventions

Control Intervention1: Nil: Nil

Sponsors

Maulana Azad Medical College and Associated Hospitals
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: ALL THE DIAGNOSED CASES OF DIFFUSE LARGE B CELL LYMPHOMA NOT ON TREATMENT.

Exclusion criteria

Exclusion criteria: ALL OTHER HEMATO-LYMPHOID MALIGNANCY

Design outcomes

Primary

MeasureTime frame
Assess the expression of CD30 by immunohistochemistry in patients with Diffuse large B-cell Lymphoma. Timepoint: 1 year—

Secondary

MeasureTime frame
Assess the prognostic significance of CD30 in Diffuse large B-cell Lymphoma by means of PROGRESSION FREE SURVIVAL RATE and 2 YEARS OVERALL SURVIVAL and to analyse its correlation with other prognostically significant biomarkers of the same.Timepoint: 1 year—

Countries

India

Contacts

Public ContactRASHMI GAUTAM

MAULANA AZAD MEDICAL COLLEGE

sarikasingh97b@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026